Changes of serum miR-223-3p in patients with oral cancer treated with TPF regimen and the prognosis were investigated. Fifty patients with oral cancer treated in the Affiliated Stomatological were enrolled in the study group, while 50 healthy subjects receiving physical examinations during the same period were enrolled in the control group. Serum expression of miR-223-3p was quantified by RT-qPCR. The diagnostic value of miR-223-3p in oral cancer was analyzed by the receiver operating characteristic (ROC) curve. Expression of miR-223-3p before and after treatment was compared. The study group was divided into the remission and the non-remission group based on the treatment outcome to analyze the predictive value of miR-223-3p. Patients were followed up for 3 years. Cox regression analysis was performed to analyze the independent prognostic factors. The relative serum miR-223-3p level was lower in the study than in the control group (P<0.001). Expression of miR-223-3p was significantly higher after treatment than before (P<0.05). Spearman's correlation analysis indicated that miR-223-3p expression before treatment gradually increased with the improvement of treatment outcome (r= 0.617, P<0.001). The miR-223-3p level was markedly higher in the remission than in the non-remission group (P<0.05). The area under the ROC curve of miR-223-3p was 0.797. Multivariate Cox regression analysis demonstrated that the degree of differentiation [HR: 11.862 (95% CI: 2.730-51.547)] and miR-223-3p [HR: 3.489 (95% CI: 1.447-8.413)] were independent prognostic factors. The 3-year survival of patients with high differentiation and high miR-223-3p expression was significantly higher than that of patients with poor differentiation and low miR-223-3p expression (P<0.05). In conclusion, miR-223-3p expression is low in oral cancer, and it shows potential for predicting the efficacy and prognosis of patients with oral squamous cell carcinoma (OSCC) after TPF regimen.
Introduction
Oral cancer is a common oral and maxillofacial malignant tumor, among which oral squamous cell carcinoma (OSCC) is the most prevalent (1, 2) . The reported annual new cases of OSCC are over 300,000 (3) . The diagnosis and treatment of OSCC are advancing due to the development in medical fields, but the prognosis is not very good. Data show that the 5-year survival rate of OSCC is only 50 to 60%, and some patients have advanced disease and local metastasis at the time of diagnosis, which is not conducive to clinical treatment (4, 5) . A previous study stated that the patients with advanced oral cancer had a poor 3-year survival rate (6) . At present, the most effective treatment for patients with locally advanced OSCC suitable for resection is comprehensive treatment based on radical surgery (7) .
In recent years, chemotherapy induced by TPF regimen (Docetaxel + Cisplatin + Fluorouracil) has been a hotpot of clinical research of oral cancer (8) . TPF regimen helps to downsize the tumor and reduce the difficulty of radical operation (9) . The present clinical evaluation of solid tumors mainly depends on imaging tests, which, unlike serological tests, have a high economic cost and high difficulty in sampling, as well as certain impacts on the patient's body. Therefore, the search for a serological index to evaluate the efficacy and prognosis of patients after treatment is crucial (10) . The microRNA (miR), a non-coding short-stranded RNA, 21 to 25 nt long, can bind to the target gene 3'UTR by complementary pairing to degrade or inhibit the expression of the target gene (11) . Several studies have found that miR is differentially expressed in lung, liver, breast, oral cancer, and other cancers, and is expected to be an indicator of cancer observation and prognosis (12) (13) (14) (15) . As a member of the miR family, miR-223 was reported to be differentially expressed in oral cancer in the study by Tachibana et al (16) , and it has potential to become a diagnostic and therapeutic target in oral cancer. The study by Soga et al (17) analyzed the miR expression profile of oral squamous cell carcinoma and discovered a low miR-223 expression in patients with oral squamous cell carcinoma.
However, the potentiality of miR-223 to function as a shortterm efficacy predictor and long-term prognostic index after chemotherapy has not been studied.
This study observed the expression of miR-223-3p in patients treated with TPF chemotherapy and explored its value in predicting the efficacy of OSCC patients, aiming to provide a clinical reference.
Patients and methods
Sample collection. Fifty patients with oral cancer treated in the Affiliated Stomatological Hospital of Jiamusi University (Jiamusi, China) from March 2014 to January 2016 were enrolled in the study group (aged 50-73 years), while 50 healthy subjects receiving physical examinations during the same period in the hospital were enrolled in the control group. This study was approved by the Medical Ethics Committee of the hospital.
Inclusion criteria: Patients aged >18 years and diagnosed with OSCC by imaging and pathological biopsy; patients at stage III and IV according to TnM staging system; patients in line with the 8th edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual issued in 2017 (18) ; patients willing to cooperate with the treatment and follow-up.
Exclusion criteria: Patients with other tumors or congenital defects in liver, kidney, and heart functions; patients with estimated survival time of less than 1 month; patients with infections before the admission, patients intolerant of drugs of this treatment; patients receiving no relevant targeted anticancer treatments before this treatment.
Main instruments and drugs. Docetaxel was from Shanghai Acebright Pharmaceuticals Co., Ltd., China. Cisplatin was from guizhou Hanfang Pharmaceutical Co., Ltd., China. Fluorouracil was from Hainan Choitec Pharmaceuticals Co., Ltd., China. TRIzol reagent and the mirVana TM RT-qPCR miRnA detection kit were purchased from Invitrogen, Carlsbad, CA, USA (15590618, AM1558). TaqMan™ microRNA reverse transcription kit and the PCR instrument were purchased from Applied Biosystems, Foster, CA, USA (4366596, 4427975, 7500).
Treatment methods. Patients were treated with TPF regimen and oral radical surgery as follows: 75 mg/m 2 of docetaxel (d1), 75 mg/m 2 of cisplatin (d1), 750 mg/m 2 of 5-Fluorouracil (d1-d5). One treatment cycle comprised of 19 days and one course comprised of two cycles. The efficacy was evaluated 1 week after the chemotherapy. Radical resection of oral cancer was performed 2 weeks after the chemotherapy.
Detection of miR-223-3p expression.
A total of 5 ml of peripheral venous blood was collected from all subjects before and after the treatment. Thirty minutes later, the blood was centrifuged at 1,500 x g at 24˚C for 10 min to obtain the serum for total RnA extraction with TRIzol reagent. The purity, concentration, and integrity of total RNA were measured by UV spectrophotometer and agarose gel electrophoresis. Total RnA was reverse transcribed using the TaqMan™ microRnA reverse transcription kit in line with the kit instructions. The miR-223-3p expression in the collected cDNA was detected by mirVana™RT-qPCR miRnA detection kit and the 7500 PCR instrument. The detection system consisted of 5 μl of mirVana 5x PCR Buffer, 0.5 μl of 50x ROx™, 1 μl of cDNA, 0.5 μl of forward primer, 0.5 μl of reverse primer, and enough nuclease-free water to add the system up to 20 μl. Amplification conditions: 40 cycles of pre-denaturation at 95˚C for 3 min, denaturation at 95˚C for 15 sec, annealing and extension at 60˚C for 30 sec. Three replicate wells were set for each sample, and the experiment was carried out 3 times. In the present study, U6 was used as an internal reference, and the data were analyzed using 2 -ΔΔCq (19) .
Follow-up. The survival of patients was followed up for 3 years by telephone and clinical re-examination, and the follow-up was performed every 3 months.
Outcome measures
Main outcome measures. The expression of miR-223-3p in the study and the control group and the expression of miR-223-3p before and after treatment in the study group were monitored. The short-term clinical efficacy after treatment was divided into complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) according to the response evaluation criteria in solid tumor by WHO (20) . Patients with CR and PR were in remission, while patients with SD and PD were not in remission.
Secondary outcome measures.
Patients were divided into the remission group and the non-remission group based on efficacy. The predictive value of miR-223-3p for the efficacy was compared between the two groups before the treatment. Kaplan-Meier survival curve was used to analyze the relationship between miR-223-3p high/low expression (median value: 3.22) and OSCC survival, and Cox regression analysis was performed to analyze OSCC prognosis.
Statistical analysis. The collected data were statistically analyzed using the SPSS20.0 software and visualized using the GraphPad 7 software. The distribution of the measurement data were analyzed using the Kolmogorov-Smirnov test. The measurement data with normal distribution were expressed as the mean ± standard deviation (mean ± SD), the comparison between groups was performed using the independent sample t-test and the comparison within the group was performed by paired t-test. The count data were analyzed by the chi-square test. Spearman's test was used to analyze the relationship between miR-223-3p and clinical efficacy. ROC curve was employed to observe the diagnostic value. Kaplan-Meier survival curve was used to display the 3-year survival which was analyzed by the log-rank test. Multivariate Cox regression was conducted to explore the independent risk factors affecting the prognosis of patients. A statistical difference was recognized at P<0.05.
Results
Baseline data analysis. The study and the control group were not statistically different in sex, age, BMI, medical history, smoking, drinking, and place of residence (P>0.05) (Table I) .
Expression and efficacy predictive value of miR-223-3p in patients. According to the detection of serum miR-223-3p expression in the study and the control group, the relative serum miR-223-3p level was lower in the study than in the control group (P<0.001). The miR-223-3p expression in the study group after the treatment was significantly higher than before (P<0.05). After the treatment, no great difference was observed between the study group and the control group in the miR-223-3p expression (P>0.05).
The treatment outcome was CR in 4 patients, PR in 26, SD in 17, and PD in 3. Spearman's correlation analysis indicated that miR-223-3p expression gradually increased with the improvement of treatment outcome (r= 0.617, P<0.001).
Patients were divided into the remission group (n=30) and the non-remission group (n=20) according to the treatment outcome. The miR-223-3p level before the treatment was markedly higher in the remission group than in the non-remission group (P<0.05). The area under the ROC curve of miR-223-3p was 0.797 (21) (Fig. 1) .
Relationship between miR-223-3p and the prognosis and survival of patients. All 50 patients were followed up for three years. The number of surviving patients was 26, with a survival rate of 52.00%. Univariate Cox regression analysis indicated that the degree of differentiation and miR-223-3p expression were prognostic factors. Multivariate Cox regression analysis demonstrated that the degree of differentiation [HR: 11.862 (95% CI: 2.730-51.547)] and miR-223-3p [HR: 3.489 (95% CI: 1.447-8.413)] were independent prognostic factors. According to the survival curve of independent prognostic factors, the 3-year survival of patients with high differentiation and high miR-223-3p expression was significantly higher than that of patients with poor differentiation and low miR-223-3p expression (P<0.05) (Table II and Fig. 2 ).
Discussion
Preoperative induction chemotherapy has been proposed in recent years as a treatment program. The adoption of TPF program before the operation can control cancer cell proliferation and interfere with cell biology functions, thereby reducing the volume of solid tumors and facilitating surgical operations (22) . Presently, indexes of short-term clinical efficacy evaluation after TPF treatment are scarce. The monitoring of related indexes to predict the short-term clinical efficacy and survival will improve the prognosis of patients.
A growing number of studies have established the close relationship between the miR and the occurrence and development of various tumors (23) . miR-223-3p has low expression in a variety of tumors (24, 25) . In the study by Ding et al (26) , miR-223-3p was reported to have low expression in glioblastoma and the overexpression of miR-223-3p can effectively reduce inflammation-associated cytokines in glioblastoma to inhibit cell proliferation and migration. However, little is known about the relationship between miR-223-3p and OSCC. In the present study, we found the serum expression of miR-223-3p in OSCC patients was significantly lower than in healthy people, which is consistent with the findings of Tachibana et al (16) . The present study and that of Tachibana et al support each other, but this study is more representative and has a larger sample size. The expression of miR-223-3p after treatment was also monitored in the present study. The results demonstrated that the expression of miR-223-3p after the treatment was significantly higher than before, suggesting that the expression of miR-223-3p can be improved after TPF treatment, but its specific mechanism is not clear. The correlation analysis revealed that the expression of miR-223-3p before the treatment gradually increased with the improvement of treatment outcome, indicating that miR-223-3p expression before the treatment can function as an indicator of the efficacy of OSCC patients. We divided patients into the remission and non-remission group and found that the expression of miR-223-3p before treatment was significantly higher in the remission group than in the non-remission group. The ROC curve analysis suggested that the area under the curve of the miR-223-3p expression before the treatment for OSCC efficacy prediction was 0.797, with high predictive value. Previous literature (27, 28) states that the high expression of miR-223-3p can increase the sensitivity of cancer cells to cisplatin, docetaxel, and 5-FU. This may be one of the reasons why the efficacy in the remission group was better than in the non-remission group in this study, but the specific mechanism needs to be further studied.
Cox regression was conducted to analyze the factors affecting the prognosis of patients. The analysis showed that miR-223-3p and degree of differentiation were independent factors influencing the prognosis of patients. One previous study discovered that the degree of differentiation is related to the prognosis of patients with OSCC (29) . However, previous studies mostly focused on the difference between poor differentiation and moderate + high differentiation.
The present study made a comparison between moderate differentiation and high differentiation and believed that, like high differentiation, moderate differentiation also has an impact on the prognosis of patients. However, in the present study, the prognosis of oral cancer patients was found to be related with pathological staging but not related with the TNM staging, which is consistent with the results in the study by Chen et al (30) . We speculate that this may be the consequence of a small sample size. This study is the first to discover that miR-223-3p can be used as a potential independent prognostic indicator for OSCC.
The present study and above-mentioned studies have proven the clinical value of miR-223-3p in patients with OSCC. However, the specific mechanism of miR-223-3p were not explored and the small sample size in this study requires further study for confirmation.
In summary, miR-223-3p, expression is low in oral cancer, and it shows potential for predicting the efficacy and prognosis of patients with oral squamous cell carcinoma (OSCC) after TPF regimen.
